1	Efficacy of intravenous paracetamol and mannitol in managing chronic
2	post-thoracotomy pain in patients with lung cancer: Study protocol for a single
3	center prospective randomized double-blind controlled trial
4	
5	Xing Lu ^{1¶} , Junhui Zhou ^{1¶} , Xi Li ¹ , Jie Gao ² , Siqing Liu ³ , Wei Zhong ¹ , Gaoyuan Xi ¹ ,
6	Yingchun Guo ¹ , Hongdang Xu ^{4*}
7	
8	¹ Department of Anesthesiology, Henan Provincial Chest Hospital & Chest Hospital
9	of Zhengzhou University, Zhengzhou, China
10	² Department of Anesthesiology, Chinese Academy of Medical Sciences & Peking
11	Union Medical College, Peking, China
12	³ The Second Hospital of Tianjin Medical University, Tianjin, China
13	⁴ Department of Anesthesiology, Central China Fu Wai Hospital, Central China Fu
14	Wai Hospital of Zhengzhou University, Heart Center of Henan Provincial People's
15	Hospital, Zhengzhou, China
16	
17	Short title: Intravenous paracetamol and mannitol for post-thoracotomy pain in lung
18	cancer
19	
20	*Corresponding author
21	Email: zhicungaoyuan1985@163.com (HX)
22	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

²³ [¶] These authors contributed equally to this work and are co-first authors.

24 Funding

- 25 This trial is supported by the Henan Provincial Science and Technology Research and
- 26 Development Program Joint Fund (Applied Research Category) (No.232103810054).
- 27 The sponsor and funder had no involvement in the study design, data collection,
- 28 management, analysis, and interpretation, writing of the report, or the decision to
- 29 submit the report for publication.
- 30 **Competing interests**
- 31 The authors declare that they have no competing interests.

32 Data availability

33 During the current study, no datasets were generated or analyzed. All pertinent data34 from this study will be accessible upon its completion.

35

36 Abstract

37 Chronic post-thoracotomy pain is a common complication that affects 20% to 60% of patients who undergo surgery for lung cancer. The persistent pain affects 38 quality of life and satisfaction with surgery. Intravenous paracetamol and mannitol, 39 analgesic antipyretic properties, 40 known to have and may help relieve moderate-to-severe post-operative pain. This trial aims to assess their effectiveness 41 and safety in managing chronic post-thoracotomy pain in patients with lung cancer. 42 43 This prospective double-blind randomized controlled clinical trial will be conducted at a single center. A total of 856 patients who will undergo thoracoscopic radical 44

surgery for lung cancer will be enrolled and randomly assigned to test (intravenous 45 paracetamol and mannitol) and control (intravenous normal saline) groups in a 1:1 46 ratio (428 patients in each group). Efficacy will be evaluated in terms of the incidence 47 of chronic post-thoracotomy pain at 3 months (primary outcome). Secondary 48 outcomes will include the dosage of propofol and remifentanil, numerical rating scale 49 pain scores, number of times the patient-controlled intravenous analgesia button is 50 pressed, occurrence of post-operative nausea and vomiting and respiratory depression, 51 time to first flatus and ambulation after surgery, length of hospital stay, surgeon and 52 53 patient satisfaction, and incidence of chronic post-thoracotomy pain at 6 and 12 months after surgery. Quality of daily life will be evaluated at 3, 6, and 12 months 54 after surgery. Intention-to-treat analysis will also be conducted. The research protocol 55 56 has been reviewed and approved by the Medical Thesis Committee of Henan Provincial Chest Hospital and Chest Hospital of Zhengzhou University on April 29, 57 2023 (reference: [2023] approval number: [04-06]). The results of this trial will be 58 59 communicated to the participants and subsequently submitted for publication in peer-reviewed journals for wider dissemination. The study has been registered in the 60 Chinese Clinical Trial Registry on June 27, 2023 (registration number: 61 ChiCTR2300072869, available at https://www.chictr.org.cn/). The protocol version 62 number is Version 1.1, dated August 20, 2023. 63

64

65 Introduction

66 Chronic post-surgical pain (CPSP) is common following surgery at different sites and

may develop after abdominal, orthopedic, and cardiothoracic procedures. The surgical 67 site and methods are the primary factors that influence the incidence of CPSP [1]. 68 Thoracotomy is a procedure that allows access to the thoracic cavity. As this requires 69 dissection through multiple layers of skin, fat, and muscles, patients experience acute 70 or chronic pain after surgery; notably, thoracic surgery is associated with the highest 71 incidence of chronic pain [2]. Chronic post-thoracotomy pain (CPTP) is a persistent 72 and debilitating condition that affects a substantial number of patients who undergo 73 surgery for lung cancer. This long-term neuropathic pain mainly occurs around the 74 75 incision site [3]. As this is a type of CPSP, it is defined by persistence for at least 3 months after the procedure [4]. CPTP can significantly impact quality of life in 76 affected patients, and thereby lead to physical and psychological distress; it also 77 78 increases subsequent medical expenses and social costs. However, an incomplete understanding of its pathophysiology, a lack of personalized therapeutic strategies, 79 absence of standardized assessment criteria, inadequate long-term follow-up, and 80 deficiencies in interdisciplinary teamwork create substantial challenges to the 81 effective management of CPTP. Addressing these issues requires further research, 82 clinical evaluation, and policy support. This may help improve management of the 83 condition and patient quality of life. 84

Trauma during thoracic surgery typically involves injuries to the costal cartilage, costovertebral joints, muscles, pleura (due to traction), intercostal nerves, and lung parenchyma; thoracic drainage tubes are also a source of irritation. In conjunction, these injuries may contribute to the development of CPTP [5]. Tissue and nerve

damage can result in inflammation and edema, and directly cause symptoms of nerve 89 compression. In addition, the release of inflammatory mediators such as interleukin-6, 90 91 interleukin-8, tumor necrosis factor- α , and substance P may lower the pain threshold by enhancing pain receptor activity. This cascade ultimately results in heightened 92 93 sensitization of pain centers in the spinal dorsal horn neurons and cerebral cortex. Current understanding therefore supports the notion that the pathogenesis of CPTP 94 involves a combination of somatic, visceral, and neuropathic pain, that is often 95 accompanied by central nervous system sensitization [6]. 96

97 The presence of intense acute pain following surgery has been identified as one of the predictive risk factors for the development of CPSP [7]. Anesthesiologists therefore 98 use a variety of analgesic techniques to alleviate early post-operative pain in patients 99 100 undergoing thoracic surgery. Commonly utilized strategies include administration of thoracic epidural analgesia, intravenous non-steroidal analgesics or opioids, and 101 ultrasound-guided nerve blocks (such as paravertebral, intercostal nerve, and erector 102 spinae and serratus anterior plane blocks, among others) [8]. Among these 103 approaches, ultrasound-guided nerve blocks have gained particular popularity for 104 post-operative pain management. This may be attributed to their efficacy in providing 105 analgesia and reducing the need for opioids, both of which potentially decrease 106 opioid-related adverse effects such as post-operative nausea and vomiting [9]. 107 However, nerve block procedures require considerable skill and are associated with 108 risks of complications such as pneumothorax, hematoma, and block failure. 109 Anesthesiologists need to possess a thorough understanding of the position of 110

anatomical structures to address these challenges; this can be particularly demandingfor less experienced practitioners.

Paracetamol (acetaminophen) is a 4-p-aminophenol derivative and a type of 113 acetanilide central antipyretic analgesic. Unlike non-steroidal anti-inflammatory 114 drugs, it does not cause damage to the gastric mucosa (that causes indigestion) or 115 kidney. In addition, it does not cause the unpleasant side-effects associated with 116 opioids such as respiratory depression, nausea, vomiting, constipation, or urinary 117 retention [10]. Owing to the lesser potential for adverse reactions and high safety, it is 118 119 often the first choice for multimodal analgesia after surgery. As per the American Society of Anesthesiologists Task Force on Acute Pain Management [11], 120 post-operative patients should receive non-opioid analgesics as first-line drugs in the 121 122 absence of any contraindications; opioids are only recommended as auxiliary drugs.

The intravenous route is ideal for administration of paracetamol immediately after 123 surgery, as patients are unable to take oral drugs and/or need rapid pain relief [12]. 124 125 Previous studies have confirmed that paracetamol injections offer reliable and optimal analgesic effect, while avoiding the adverse reactions of opioids [13]. A systematic 126 review and meta-analysis comprising 5 randomized controlled trials (including 2635 127 patients) evaluated the impact of intravenous acetaminophen on post-operative pain in 128 those undergoing brain surgery. The results showed that acetaminophen significantly 129 decreased rescue analgesic consumption, total analgesic use, intensive care unit stay, 130 and visual analog scale scores, and increased patient satisfaction. Preoperative 131 administration of intravenous acetaminophen was therefore found to effectively 132

alleviate post-operative pain, reduce analgesic requirements, and improve outcomes in 133 patients undergoing brain surgery [14]. Another study on patients who underwent 134 partial mastectomy showed that the analgesic effect of intravenous acetaminophen 135 was comparable to that of flurbiprofen axetil. However, it was more effective in 136 controlling movement-induced pain at 3 h after surgery, and demonstrated a lower 137 incidence of adverse reactions [15]. Yet another study on patients who underwent 138 video-assisted thoracic surgery demonstrated that the post-operative pain control 139 offered by intravenous ketorolac and acetaminophen was comparable to that of 140 141 morphine. Notably, the combination offered superior pain control compared to morphine within 2 hours of surgery, and was not associated with any significant 142 adverse reactions [16]. Nevertheless, there is a paucity of long-term follow-up data 143 144 regarding the use of intravenous acetaminophen. The available studies mainly focus on short-term outcomes, and do not provide crucial long-term follow-up data that are 145 necessary for assessing the sustained effectiveness and safety profile of this drug. 146

In China, intravenous paracetamol and mannitol was introduced as a novel analgesic combination in 2022. The primary component is the 4-aminophenol derivative, which is known for its analgesic and antipyretic properties [17] and effectively complements opioid analgesics in managing moderate-to-severe post-operative pain in adult patients. The combined analgesic and anti-inflammatory effects of intravenous paracetamol and mannitol show promise in preventing the onset and reducing the progression of CPTP.

154 The aim of this trial is to evaluate and compare the efficacy and safety of

intravenous paracetamol and mannitol versus normal saline in alleviating CPTP in
patients with lung cancer. The findings of this trial may help provide crucial clinical
evidence for diversifying management strategies in CPTP; this may in turn improve
treatment outcomes and quality of life.

159

160 Materials and methods

161 Study design

This single-center prospective randomized double-blind controlled trial will adopt a 162 parallel group design. It will aim to investigate the efficacy of intravenous 163 paracetamol and mannitol in managing CPTP among patients who undergo surgery 164 for lung cancer. To maintain the double-blind design, neither the researchers nor the 165 166 participants will be aware of the assigned study group. This will reduce the impact of subjective bias and ensure objectivity of the results. This trial was registered in the 167 Chinese Clinical Trial Registry on June 27, 2023, with a registration number of 168 169 ChiCTR2300072869.

170 **Type of trial**

In this parallel-group design trial, participants will be randomly assigned to one of
two groups: test group (receiving intravenous paracetamol and mannitol) and control
group (receiving normal saline).

174 Allocation ratio

Participants will be allocated to either group in a ratio of 1:1; this implies that anequal number of participants will be allocated to each group.

177 Framework

This superiority trial aims to demonstrate superiority of the intervention agent 178 179 (intravenous paracetamol and mannitol) over the control agent (normal saline) in achieving control of CPTP in patients with lung cancer. The study will assess the 180 effectiveness of the intervention in reducing pain intensity and improving overall 181 quality of life (compared to the control). The investigators will strictly adhere to the 182 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 183 guidelines [18] (available for reference the official website: 184 on 185 https://www.spirit-statement.org). The Checklist. SPIRIT checklist can be found in S1 File. 186

187

188 **Participants**

This trial will be implemented in an academic hospital, and the data will be collected in China. The eligibility criteria were determined by a researcher who will not be associated with the study; the selected criteria are based on patient parameters at admission. Patients enrolled in this study or their authorized representatives will be required to sign an informed consent form by a trained researcher prior to initiation of treatment. The template for the informed consent form can be found in S2 File.

Patients will be eligible for inclusion if they: 1) are aged between 18 and 64 years;
2) are diagnosed with lung cancer before surgery (or during surgery via rapid frozen
pathological examination) and are scheduled to undergo thoracoscopic surgery (such
as lobectomy, wedge resection, or anatomic segmentectomy); 3) have American

199 Society of Anesthesiologists grade I–III physical status; and 4) are able to understand 200 the purpose of the study, agree to participate, and provide written informed consent.

201 Patients will be excluded from this trial if they: 1) only receive conservative treatment without surgery during hospitalization; 2) have any mental illness or 202 cognitive impairment and are unable to cooperate with the study requirements; 3) are 203 diagnosed with severe coagulation dysfunction; 4) have any serious infections; 5) are 204 dependent on drugs or have a history of long-term use of psychotropic drugs; 6) have 205 a history of long-term use of steroids or hormonal agents; 7) have Gilbert syndrome; 206 207 8) have an inadequate hepatic glutathione reserve due to chronic malnutrition, 9) suffer from glucose-6-phosphatase anorexia, overeating, or cachexia; 208 dehydrogenase deficiency, which may lead to hemolytic anemia; and 10) are allergic 209 210 to acetaminophen, mannitol, or other anesthetic drugs.

Trial participation may be terminated if: 1) patients or their families actively request for withdrawal from the study during the study period; 2) temporary thoracotomy closure is necessary during the operation; 3) patients develop severe heart, brain, liver, or kidney dysfunction after surgery; 4) any of the following events occur: failed post-operative recovery, automatic discharge, or perioperative death; and 5) patients or their families cannot be contacted on three or more occasions during the follow-up period.

218

219 **Randomization**

A computer-generated randomization table will be used to create group random

sequences. The random sequences will be generated by independent researchers and stored in secure electronic files to ensure confidentiality of grouping information. The generation of random sequences will ensure that participant grouping is random and unpredictable.

Factors for stratification will include age, gender, and pain severity. To reduce predictability of the random sequence, details of any planned restrictions (such as blocking) will be outlined in a separate document that cannot be accessed by those involved in participant enrollment or intervention assignment.

229 The specific steps will be as follows: a) a computer will be used to generate random numbers in advance; these will be placed in sequentially numbered, sealed, opaque 230 envelopes which will be managed by designated personnel, b) the patients who meet 231 232 the inclusion criteria will be numbered according to the order of enrollment, c) random numbers will be matched with those of the patient to obtain the allocated 233 group, d) the results of randomized grouping will be handed over to an anesthesia 234 nurse, who will provide either acetaminophen and mannitol for intravenous 235 administration or normal saline. The appearance, packaging, and labeling of these two 236 drugs will be identical. The syringes will only be labeled as "test drugs" to ensure that 237 the patients, anesthesiologists, and outcome assessors are unaware of the allocated 238 group. The anesthesiologist will administer the drugs in sequential order. The random 239 coding table for the clinical trial (known as a blind bottom) will be kept at the Clinical 240 241 Trial Center of the Henan Provincial Chest Hospital & Chest Hospital of Zhengzhou University. 242

Sequentially numbered opaque sealed envelopes will be used to conceal the 243 sequence, and each envelope will contain a unique allocation code corresponding to 244 245 either the paracetamol and mannitol or normal saline groups. These envelopes will be opened sequentially by a designated research pharmacist only at the time of 246 participant enrollment and assignment to ensure allocation concealment. The 247 allocation codes will not be disclosed to the investigators, participants, or outcome 248 assessors until study completion. This will prevent disclosure of grouping information 249 during the allocation process, and ensure appropriate randomization and blinding. 250

251

252 Blinding

All anesthesiologists, anesthesia nurses, beneficiaries, and personnel involved in data collection and analysis will be blinded. An anesthesiologist who will be blinded to patient grouping will conduct the follow-up assessments for acute and chronic post-operative pain. The Data Monitoring Committee will establish and supervise emergency unblinding procedures to ensure study integrity.

258

259 Interventions

260 Anesthetic management

All patients will receive anesthesia as per standardized protocols. Routine monitoring of the blood pressure, electrocardiogram, and oxygen saturation will be performed after the patient enters the operating room. Venous access will be established and invasive arterial blood pressure monitoring will be performed. All

patients will be administered combined intravenous and inhalational anesthesia. The 265 following drugs will be administered intravenously during induction: midazolam 266 (0.04 mg/kg), etomidate (0.3 mg/kg), sufentanil (0.4 µg/kg), and rocuronium (0.8 267 mg/kg). Double-lumen endotracheal intubation will then be performed under visual 268 guidance for mechanical ventilation. Following successful tracheal intubation, right 269 internal jugular vein cannulation will be performed under ultrasound guidance. The 270 bispectral index will be monitored continuously during surgery to ensure that the 271 values are maintained within a range of 40-60. Inhalational sevoflurane (1%) will be 272 administered along with propofol (4–8 mg \cdot kg⁻¹·h⁻¹ by continuous infusion), 273 remifentanil (0.05–0.2 μ g·kg⁻¹·min⁻¹), and rocuronium (0.3–0.6 mg·kg⁻¹·h⁻¹). The 274 tidal volume, respiratory rate, positive end-expiratory pressure, and fraction of 275 276 inspired oxygen will be adjusted as appropriate. Balanced crystalloid fluids will be continuously infused at a rate of 3 ml·kg $-1\cdot$ h⁻¹ to maintain urine outputs of > 0.5 277 ml·kg⁻¹·h⁻¹. Rocuronium will be discontinued 30 min before the end of surgery, and 278 279 sugammadex will be used for reversing neuromuscular blockade. The double-lumen endotracheal tube will then be removed, and a patient-controlled intravenous 280 analgesia (PCIA) pump will be connected to the intravenous access before 281 transferring the patient to the post-anesthesia care unit (PACU). All patients will 282 undergo thoracoscopic radical resection of the malignant lung lesion, and the 283 procedures will be performed by the same group of surgeons. 284

285 Study interventions

Patients in the test group will be administered intravenous paracetamol (500 mg)

and mannitol 15 min before the end of the operation; they will also be administered intravenous paracetamol (500 mg) and mannitol on post-operative days 1 and 2, respectively. Patients in the control group will be administered intravenous normal saline (50 mL) at the same time points.

291

292 Pain management

Patients in both groups will be administered intravenous oxycodone (5 mg) 15 min 293 before the end of surgery and PCIA immediately after surgery. The medications in the 294 295 analgesic pump will include sufertanil (2.5 µg/kg) and tropisetron (10 mg), and will be diluted with normal saline to achieve a total volume of 100 mL. The following 296 analgesic pump parameters will be used: background dose: 2 µg/h, single dose: 2 297 298 µg/time, and lockout time: 15 min. The patients will be instructed to press the button on the intravenous analgesia pump (as a remedial analgesic measure) when the 299 numeric rating scale (NRS) scores for pain will reach \geq 4 points. 300

301

302 Outcome measures

The investigators will communicate with each patient on preoperative day 1, and will provide guidance regarding the use of PCIA pumps. The NRS will be used to evaluate pain intensity in all cases [19]. In this context, the NRS is a commonly used scoring tool that helps assess the intensity of pain experienced by patients. The intensity is scored on a scale of 0 to 10, where 0 and 10 indicate no pain and the most severe pain, respectively. Patients will be asked to select a number to describe their

current level of pain. Usually, scores of 0, 1–3, 4–6, 7–9, and 10 indicate no, mild,
moderate, severe, and the most severe pain, respectively.

311 Efficacy will be measured in terms of the incidence of CPTP at 3 months after surgery; this will be the primary outcome measure of this study. Individuals who meet 312 the diagnostic criteria for CPSP based on the International Association for the Study 313 of Pain (International Classification of Diseases-11) standards will be recruited [4]. 314 Notably, CPSP is defined as pain that persists or increases in intensity for more than 3 315 months following surgery or tissue injury (including any trauma such as burns). The 316 317 pain may not be limited to the original surgical or injury site, and may radiate to the entire area innervated by the nerves that supply that region (e.g., deep somatic or 318 visceral tissues). Other potential causes of pain, such as acute or chronic infections, 319 320 malignant tumors, or pre-existing chronic pain conditions must be excluded before a diagnosis of CPSP can be made. Although the pain is typically neuropathic by nature, 321 and neuropathic pain mechanisms play a significant role in the pathogenesis, the 322 323 condition should be diagnosed as CPSP and not neuropathic pain. The etiology needs to be identified, and a diagnosis of chronic primary pain should be made if the cause 324 cannot be determined. 325

The secondary outcomes will include the dosage of propofol and remifentanil used; NRS pain scores at PACU entry, 30 min after PACU entry, and after surgery (at 12 h, 24 h, and 48 h); number of times the PCIA button is pressed within 24 h and 48 h after surgery; the occurrence of post-operative nausea and vomiting, and other adverse reactions including headache, insomnia, itching, respiratory depression, excessive

331	sedation, urinary retention, allergic reactions, liver injury, and kidney injury;											
332	post-operative bowel movement and ambulation times; length of hospital stay;											
333	surgeon and patient satisfaction; and the incidence of CPTP at 6 and 12 months after											
334	surgery.											
335	In the context of post-operative follow-up, the NRS pain scores can be used during											
336	telephone interviews conducted at 3, 6, and 12 months after surgery. These interviews											
337	will mainly focus on the assessment of any pain experienced by the patient at the											
338	surgical site (NRS score > 0).											
339	The impact of pain on patient quality of daily life will also be evaluated, and the											
340	degree will be categorized as follows: no, mild, moderate, and severe [20]. The level											
341	of intervention required to manage the pain will also be assessed using the following											
342	grading system:											
342 343	grading system: Grade A: No intervention required											
342343344	grading system: Grade A: No intervention required Grade B: Rest or reduction in activity											
342343344345	grading system: Grade A: No intervention required Grade B: Rest or reduction in activity Grade C: Self-administered medications											
342343344345346	grading system: Grade A: No intervention required Grade B: Rest or reduction in activity Grade C: Self-administered medications Grade D: Medical help needed from a healthcare professional											
 342 343 344 345 346 347 	<pre>grading system: Grade A: No intervention required Grade B: Rest or reduction in activity Grade C: Self-administered medications Grade D: Medical help needed from a healthcare professional A range of efficacy and adverse outcome variables will be selected as observational</pre>											
 342 343 344 345 346 347 348 	grading system: Grade A: No intervention required Grade B: Rest or reduction in activity Grade C: Self-administered medications Grade D: Medical help needed from a healthcare professional A range of efficacy and adverse outcome variables will be selected as observational indicators to comprehensively assess differences between the control and intervention											
 342 343 344 345 346 347 348 349 	grading system:Grade A: No intervention requiredGrade B: Rest or reduction in activityGrade C: Self-administered medicationsGrade D: Medical help needed from a healthcare professionalA range of efficacy and adverse outcome variables will be selected as observationalindicators to comprehensively assess differences between the control and interventiongroups. This will help evaluate the efficacy of intravenous paracetamol and mannitol											
 342 343 344 345 346 347 348 349 350 	grading system:Grade A: No intervention requiredGrade B: Rest or reduction in activityGrade C: Self-administered medicationsGrade D: Medical help needed from a healthcare professionalA range of efficacy and adverse outcome variables will be selected as observationalindicators to comprehensively assess differences between the control and interventiongroups. This will help evaluate the efficacy of intravenous paracetamol and mannitolin the management of CPTP. These outcome variables will not only help in presenting											
 342 343 344 345 346 347 348 349 350 351 	grading system: Grade A: No intervention required Grade B: Rest or reduction in activity Grade C: Self-administered medications Grade D: Medical help needed from a healthcare professional A range of efficacy and adverse outcome variables will be selected as observational indicators to comprehensively assess differences between the control and intervention groups. This will help evaluate the efficacy of intravenous paracetamol and mannitol in the management of CPTP. These outcome variables will not only help in presenting the data, but will also reflect the critical impact on patient health and post-operative											

primary outcome variable, as this parameter directly reflects the effectiveness of post-operative pain management; this in turn has significant influence on patient quality of life and the recovery process. Adverse outcome variables such as post-operative nausea and vomiting and respiratory depression, among others (which are common post-operative complications) were selected for this trial. Assessment of the incidence of these complications may offer a more comprehensive understanding on the safety and practicality of the intervention measures.

360

361 Adverse events

Patient safety will be closely monitored throughout the study. Adverse events and side effects will be assessed and recorded using a standardized evaluation tool. These events and side effects may include drug allergies, abnormal liver function, and renal dysfunction. Any adverse events or side effects will be promptly reported to the study team and appropriate measures will be taken to ensure patient safety.

An independent safety monitoring committee will be established to oversee and evaluate patient safety throughout the study. This committee will review all reported adverse events and side effects and provide recommendations for any necessary adjustments to the study protocol.

371

372 Auditing

The trial conduct will be regularly audited by an independent team to ensure compliance with the protocol, Good Clinical Practice (GCP) guidelines, and

regulatory requirements. Audits will be conducted quarterly, reviewing study documentation and verifying data accuracy and completeness through on-site visits. Any deviations will be documented and addressed promptly. The auditing process will be independent from investigators and the sponsor, reporting directly to the Institutional Review Board (IRB). Audit findings will be used to identify areas for improvement and implement corrective actions to ensure study validity and reliability.

381

382 Study protocol and data collection

- Recruitment, intervention, assessment, and participant visits will be performed as per
 the following schedule:
- 385 Enrollment

Patients will be enrolled over a period of 12 months, between July 1, 2023 and April

1, 2024. The flow chart of the trial is shown in Figure 1.

388 Interventions

389 Patients will receive the assigned intervention (intravenous paracetamol and mannitol

390 or normal saline) during thoracoscopic radical surgery for lung cancer.

391 Assessments

Primary outcome assessment for the incidence of CPTP will be performed at 3 months after surgery. Secondary outcome assessments (including dosage of propofol and remifentanil, NRS pain scores, number of times the PCIA button is pressed, occurrence of post-operative nausea and vomiting, respiratory depression, time to first flatus and ambulation, length of hospital stay, surgeon and patient satisfaction, and

incidence of CPTP at 6 and 12 months after surgery) will be conducted at specific 397 time points as outlined in the study protocol. 398

Participant visits 399

Participants will be followed up at 3, 6, and 12 months after surgery to evaluate their 400 quality of daily life. Fig 1 shows the schedule of enrollment, interventions, 401 assessments, and participant visits. This table provides a visual representation of the 402 study timeline and can help ensure adherence to the SPIRIT guidelines. 403

404

Data management and monitoring 405

In this clinical trial, meticulous planning and execution of data entry, coding, security, 406 and storage procedures are essential for safeguarding the integrity and confidentiality 407 408 of research data. A robust data management framework will be employed for this trial, and it will be overseen by a dedicated team of experts. Key components of this 409 framework will include an electronic data capture (EDC) system for data entry, 410 stringent quality control measures such as double data entry by independent personnel, 411 and rigorous data validation checks to uphold data accuracy. Data management will 412 involve the following specific operational processes: 413

414

Data entry procedures

Trained research personnel will input data into a secure EDC system, and a dual data 415 entry process will be employed to minimize errors. In cases of discrepancies, data 416 entry operators will perform source data verification to ensure accuracy and 417 consistency. 418

419 **Coding practices**

420 All collected data will be systematically coded using a standardized coding manual to 421 facilitate uniformity and precision in subsequent data analysis. To protect patient 422 confidentiality, any personally identifiable information will be anonymized and 423 replaced with unique study identification numbers.

424 **Data security measures**

Access to the study database will be strictly controlled and limited to authorized personnel. Data will be stored securely on protected servers with restricted access controls and regular backups to prevent data loss or unauthorized access.

428 **Data storage protocols**

Electronic data will be housed in a password-protected database with encryption protocols to uphold confidentiality and data security. Physical copies of sensitive study documents will be stored in locked filing cabinets within a secure office environment.

433 Enhancing data quality

The EDC system will be equipped with range checks to validate data values; this will ensure accuracy and completeness. Routine data monitoring and quality control assessments will be conducted to promptly identify and rectify any discrepancies or missing entries.

438 Availability of data management procedures

439 Detailed data management protocols including the areas of data entry, coding,
440 security, and storage guidelines have been comprehensively outlined in the Data

Management Plan document. This document, which delineates specific procedures for
handling research data, can be obtained upon request from the principal investigator
or the research team.

444

Data collection plan: retention

During the informed consent process, we will provide detailed information to all participants about the study objectives, procedures, potential risks, and benefits. To ensure participant retention and progress monitoring, we will schedule regular follow-up visits or phone calls, reminding them of subsequent appointments. Additionally, we will assign a dedicated study coordinator to address participants' concerns, answer questions, and provide necessary support throughout the study.

451 **Data monitoring: formal committee**

452 The Data Monitoring Committee (DMC) will consist of members with diverse professional backgrounds, including clinical experts, statisticians, and independent 453 ethics experts, ensuring a comprehensive and proficient evaluation of research data. 454 455 The roles and responsibilities of the DMC will be clearly outlined, emphasizing their duties in monitoring data integrity, accuracy, and safety, evaluating interim analysis 456 results, and providing impartial advice. A structured reporting mechanism will be 457 established to keep the research team and stakeholders informed about the study's 458 progress and potential issues. The independence of the DMC from the sponsor will be 459 explicitly stated, upholding the credibility and transparency of research data and 460 ensuring the reliability of the findings of this trial. 461

462

463 Sample size calculation

The sample size for this study was estimated based on the incidence of CPSP in 464 patients who undergo surgery for lung cancer at 3 months after surgery (the primary 465 indicator for evaluation of efficacy). In this randomized controlled trial, the 466 experimental group will receive intravenous paracetamol and mannitol and the control 467 group will receive normal saline. Studies have shown that the incidence of CPTP 468 ranges from 25% to 57% [3]. It may therefore be assumed that 50% of patients in the 469 control group would develop CPTP at 3 months after surgery. As the pre-trial showed 470 471 the incidence of CPSP in the trial group to be 40%, this was set as the incidence rate for sample size calculation. Based on a bilateral α value of 0.05 and power (1- β) of 472 0.8, the sample size ratio between the experimental and control groups was calculated 473 474 to be 1:1. The sample size was estimated using R, as per the method proposed by Chow et al. [21]. Calculations showed the required sample size in each (intervention 475 and control) group to be 385 cases. On considering a 10% loss-to-follow-up rate, a 476 477 minimum of 428 cases will be required in either group; a total of 856 cases will therefore be included in this trial. 478

479

480 Statistical analysis

SPSS 19.0 statistical software (IBM Corporation, Armonk, NY, USA) will be used for all statistical analyses. The two-tailed P value will be used to test for statistical significance; P < 0.05 will be considered statistically significant. The following statistical analysis methods will be employed:

485 **Descriptive analysis**

- 486 Descriptive statistical analysis will be performed using the demographic variables of 487 the study population including age, sex, and weight. The mean and standard deviation 488 will be reported for continuous variables, and the frequency and percentage will be 489 reported for categorical variables. Normality will initially be tested using the Shapiro– 490 Wilk test. Data conforming to a normal distribution will be presented as means \pm 491 standard deviation; other data will be presented as medians with interquartile ranges.
- 492 **Baseline comparisons**

The t- or Mann–Whitney U tests (depending on data normality) will be used to compare baseline continuous variables in either group. The chi-square or Fisher's exact tests will be used to compare intergroup differences between categorical variables.

497 **Primary outcome analysis**

The primary outcome measure, namely, the incidence of CPTP at 3 months after surgery, will be compared between the test and control groups using appropriate statistical tests (the chi-square or Fisher's exact tests). Logistic regression may be employed to adjust for potential confounders, as appropriate.

502 Secondary outcome analysis

503 For continuous variables (such as the dosage of propofol and remifentanil, NRS pain 504 scores, number of times the PCIA button is pressed, time to first flatus and ambulation 505 after surgery, length of hospital stay, and quality of daily life scores), the means or 506 medians will be compared between the two groups using t- or non-parametric tests as

507 appropriate.

Categorical variables including the occurrence of post-operative nausea and vomiting, respiratory depression, surgeon and patient satisfaction, and the incidence of CPTP at 6 and 12 months after surgery will be compared using the chi-square test or logistic regression.

512 The safety of intravenous paracetamol and mannitol will be evaluated; this will

513 include the incidence of adverse events and complications. The chi-squared or

514 Fisher's exact tests will be used to determine differences between the two groups.

515 Missing data handling

- 516 Missing data will be handled using appropriate methods (such as multiple imputation
- or sensitivity analysis) to assess the impact of missing data on the results.

518 Subgroup analysis

- 519 Subgroup analyses may be conducted based on relevant factors (such as age, sex, type
- of lung cancer, and preoperative pain scores) to explore potential effect modifiers.

521 Multiplicity adjustment

522 To control the overall type I error rate, adjustment for multiple comparisons may be

523 considered using methods such as the Bonferroni correction.

524 Interim analysis

Interim analyses will be conducted when 50% and 75% of patients complete the 3-month follow-up, focusing on the primary outcome and safety concerns. An independent Data and Safety Monitoring Board (DSMB) will review these results and provide recommendations. The trial may be stopped early based on statistically

significant differences in the incidence of CPTP, safety concerns, or futility, with the

final decision made by the Principal Investigator in consultation with the DSMB.

531 Intent-to-treat (ITT) analysis

An ITT analysis will be performed to reduce the impact of bias and increase reliability 532 of the results. Data processing and statistical analysis will be performed in strict 533 adherence with the principles of ITT analysis. All participants will be grouped 534 according to the initial random allocation, regardless of full adherence to the 535 treatment protocol. Appropriate methods will be employed to handle any missing data; 536 537 this will ensure reliability and objectivity of the analysis. For instance, in cases where a participant has missing follow-up data, suitable methods such as sensitivity analysis 538 will be used based on the initial grouping to assess the impact on the results; 539 540 appropriate explanations will also be provided during result interpretation.

541

542 Interventions: modifications

All protocol modifications, including changes to eligibility, outcomes, or analyses, will be promptly communicated to investigators, submitted to the Research Ethics Committees (REC)/IRB for approval with detailed rationale and impact assessment, disclosed to participants via updated informed consent, updated in trial registry (Chictr.org.cn.) for transparency, reported in publications, and documented with access for investigators and the trial team to ensure compliance and transparency.

549

550 **Interventions: adherance**

In this trial, strategies such as education and training, regular monitoring and follow-up, provision of support tools like a calendar, establishment of 24-hour communication channels, and consideration of rewards and incentives will be used to improve patient compliance with the intervention, ultimately ensuring the accuracy and effectiveness of the research results.

556

557 Interventions: concomitant care

558 During the trial, participants will be allowed to receive routine analgesic therapy, 559 including morphine or other common analgesics, as well as non-interventional pain 560 management methods. They will also be able to receive necessary rehabilitation 561 programs and postoperative care guidance. However, they will be prohibited from 562 taking other experimental analgesic drugs or treatments and from participating in 563 other clinical research projects simultaneously, to ensure the accuracy of the results of 564 this trial.

565

566 Ancillary and post trial care

Participants in this study will receive standard of care for lung cancer and post-thoracotomy pain management, as well as necessary ancillary care throughout the trial and a reasonable post-trial period. Post-trial, they will transition back to regular care providers, with the study team remaining available for guidance and support. A comprehensive compensation plan is in place to protect participants' rights and welfare, covering medical expenses and other reasonable costs in case of harm

directly attributable to trial participation. Adverse events will be promptly reported,
investigated, and resolved, with the study sponsor initiating timely and fair
compensation when necessary.

576

577 Ethics and dissemination

This trial has been approved by the Ethics Committee of the Henan Provincial Chest 578 Hospital & Chest Hospital of Zhengzhou University on April 29, 2023 (approval 579 number: (2023) EC (04-06)]. The medical ethics approval can be found in Supporting 580 581 information S3.Written and informed consent will be obtained from all participants prior to their inclusion in this trial. All participants will be provided with detailed 582 information regarding the study objectives, procedures, potential risks and benefits, 583 584 confidentiality measures, and their right to withdraw from the study at any time. The confidentiality and privacy of participants will be strictly maintained throughout this 585 trial, and it will be conducted in accordance with ethical principles and regulations to 586 ensure that the rights and well-being of all participants are protected. 587

The results of this trial will be communicated to the participants and subsequently submitted for publication in peer-reviewed journals for wider dissemination. The investigators will actively participate in relevant academic conferences and seminars to share research methodologies and achievements with peers; this will foster academic exchange and collaboration.

593

594 **Discussion**

The combination of intravenous paracetamol and mannitol characteristically 595 demonstrates rapid onset (peak time of 15 min), high blood drug concentrations (C_{max} 596 of 25–30 µg/mL for a single adult dose of 1000 mg injection), lack of first-pass effect, 597 predictable pharmacokinetics, broad applicability, and efficacy in pain management. 598 Although the traditional view attributed the analgesic action of paracetamol to 599 cyclooxygenase inhibition [22], recent research indicates that the primary mechanism 600 involves the metabolism of N-acylphenol amine (AM404), which subsequently 601 interacts with transient receptor potential vanilloid 1 and cannabinoid 1 receptors in 602 603 the brain. The paracetamol metabolite (AM404) directly induces analgesia via the transient receptor potential vanilloid 1 receptor at the C-fiber terminals in the spinal 604 dorsal horn [23]. In view of the characteristics and mechanisms of action, the novel 605 606 combination of intravenous paracetamol and mannitol demonstrates superior analgesic effects and a lower incidence of adverse reactions; this makes it a safe and 607 effective option for pain management. This trial will therefore aim to evaluate the 608 609 efficacy and safety of the combination in managing CPTP; the results are expected to provide providing valuable insights for future clinical practice. 610

This trial will focus on effective data collection and accurate interpretation of clinical outcomes, as the effectiveness of data collection is essential for research reliability. It is also essential that the issue of missing data is effectively addressed; transparency will therefore be maintained while reporting the extent of missing data, and robust strategies (such as data imputation and sensitivity analyses) will be employed to reduce bias. Rigorous methodology (such as double data entry and

validation checks) will be followed to minimize data entry errors and enhance data 617 quality. The clinical relevance of outcome variations across different cohorts will be 618 elucidated while interpreting clinical outcomes; this will provide insights into patient 619 care implications. For instance, superior pain scores in the intervention group may 620 suggest reduced reliance on analgesics; this can minimize medication-related adverse 621 effects. Our analysis will contextualize the clinical significance of findings; this will 622 enable comparisons with findings in existing literature, and thereby improve 623 comprehension and applicability. As it is crucial to address study limitations 624 625 (including potential bias related to selection and information), these will be discussed and their impact on outcomes will be evaluated; this will help ensure that the 626 interpretations are comprehensive. Adequate sample size determination is key to 627 628 robust statistical analyses and reliable conclusions. The rationale behind sample size determination has therefore been discussed; the impact of sample size inadequacy on 629 study outcomes has also been described. 630

631 The findings of this study will have significant clinical implications as it aims to evaluate the efficacy of a new combination, namely, intravenous acetaminophen and 632 mannitol, in managing CPTP following surgery for lung cancer. The findings will 633 have the potential to influence clinical practice in several key ways. First, 634 confirmation of the effectiveness of acetaminophen and mannitol in alleviating CPTP 635 could help optimize clinical treatment strategies. This new treatment option may be 636 integrated into post-operative pain management protocols for those undergoing lung 637 cancer surgery, and may thereby enhance patient care. Second, confirmation of 638

superiority of the combination could help reduce the use of propofol and remifentanil 639 for analgesia. This may in turn reduce the frequency of drug-related side effects and 640 complications, and thereby improve post-operative comfort and expedite recovery; 641 this may provide substantial clinical benefits. Finally, evaluation of the impact of the 642 novel combination on quality of life will offer a more comprehensive understanding 643 of the post-operative experience. If intravenous acetaminophen and mannitol are 644 found to improve patient quality of life, the findings could provoke renewed focus on 645 post-operative care practices and enhance overall patient well-being. 646

647 Conclusion

In conclusion, this study protocol outlines a rigorous and comprehensive approach for evaluating the efficacy and safety of intravenous paracetamol and mannitol in managing CPTP after surgery for lung cancer. The study will employ a randomized double-blind controlled design to provide reliable evidence regarding the potential benefits of this treatment approach. The findings will contribute to the existing literature on CPTP management, and may have important implications for improving patient outcomes and quality of life.

655

656 Strengths and limitations

The rigorous design of this trial (single-center, randomized, double-blind, and controlled) will ensure high standards for evaluating drug efficacy. Randomization and blinding will minimize bias, and the control group will allow for direct comparison to accurately assess efficacy. Standardized pain assessment tools will

ensure consistency and reliability of outcome measurements. In addition, the
single-center design will minimize variability and improve internal validity; however,
this may limit generalizability.

The limitations of this trial include potential issues with the sample size, selection bias, generalizability, compliance, and the resource-intensive nature of design and execution.

667

668 Author contributions

JZ and XL will jointly contribute to the design and financial support of this trial, and 669 have also jointly contributed to writing and revision of the manuscript. These two 670 authors have contributed equally to the work and are co-first authors. JG and SL will 671 672 be responsible for data analysis and will provide relevant research recommendations. WZ and GX will be responsible for the specific implementation of the research 673 program. YG will assist in data collection. HX will be responsible for the design and 674 quality control of the study, provide relevant research suggestions, and participate in 675 manuscript revision. All authors will contribute to the completion of the study and the 676 writing of the manuscript. All authors agree to be accountable for the content of the 677 work. 678

679

680 Acknowledgements

The authors would like to thank Xia Gao and Xiao-bo Wang for their contributions toresearch quality assurance and data validation.

```
683
```

684 Supporting information

- 685 S1 Checklist. SPIRIT checklist.(DOC)
- 686 S1 Protocol. Study protocol.(DOCX)
- 687 S2 The template for the informed consent form
- 688 S3 Medical Ethics Approval

689

- 690 Patient and public involvement
- 691 Patients and/or the public were not involved in the design, or conduct, or reporting, or
- 692 dissemination plans of this trial.

693

- 694 **Patient consent for publication**
- 695 Not required.

696

697 **References**

1. Lopes A, Seligman Menezes M, Antonio Moreira de Barros G. Chronic

699 postoperative pain: ubiquitous and scarcely appraised: narrative review. Braz J

- 700 Anesthesiol. 2021;71: 649-655.
- Marshall K, McLaughlin K. Pain management in thoracic surgery. Thorac
 Surg Clin. 2020;30: 339-346.
- 3. Gupta R, Van De Ven T, Pyati S. Post-thoracotomy pain: current strategies for
- prevention and treatment. Drugs. 2020;80: 1677-1684.

- 4. Schug SA, Lavand'homme P, Barke A, Korwisi B, Rief W, Treede RD. The
- 706 IASP classification of chronic pain for ICD-11: chronic postsurgical or
- 707 posttraumatic pain. Pain. 2019;160: 45-52.
- 708 5. Reznik SI. Post-thoracotomy pain and nerve protection: back to the drawing
 709 board? J Thorac Cardiovasc Surg. 2019;157: 376-377.
- 6. Wildgaard K, Ravn J, Kehlet H. Chronic post-thoracotomy pain: a critical
 review of pathogenic mechanisms and strategies for prevention. Eur J
 Cardiothorac Surg. 2009;36: 170-180.
- 7. Fortier S, Hanna HA, Bernard A, Girard C. Comparison between systemic
 analgesia, continuous wound catheter analgesia and continuous thoracic
 paravertebral block: a randomised, controlled trial of postthoracotomy pain
 management. Eur J Anaesthesiol. 2012;29: 524-530.
- 8. Mijatovic D, Bhalla T, Farid I. Post-thoracotomy analgesia. Saudi J Anaesth.
 2021;15: 341-347.
- 719 9. Coppens S, Eochagain AN, Hoogma DF, Dewinter G. Stranger things: the
 720 erector spinae block, extra sensory perception, or paranormal block by proxy?
 721 APS. 2023;1:12. doi: 10.1007/s44254-023-00007-5.
- Pasero C, Stannard D. The role of intravenous acetaminophen in acute pain
 management: a case-illustrated review. Pain Manag Nurs. 2012;13: 107-124.
- 11. American Society of Anesthesiologists Task Force on Acute Pain
 Management. Practice guidelines for acute pain management in the
 perioperative setting: an updated report by the American society of

727	anesthesiologists	task	force	on	acute	pain	management.	Anesthesiology.
728	2012;116: 248-27	3.						

- 12. Singla NK, Hale ME, Davis JC, Bekker A, Gimbel J, Jahr J, et al. IV
 acetaminophen: efficacy of a single dose for postoperative pain after hip
 arthroplasty: subset data analysis of 2 unpublished randomized clinical trials.
 Am J Ther. 2015;22: 2-10.
- Nishimoto RN. OFIRMEV: an old drug becomes new again. Anesth Prog.
 2014;61: 99-102.
- Ghaffarpasand F, Dadgostar E, Ilami G, Shoaee F, Niakan A, Aghabaklou S,
 et al. Intravenous acetaminophen (paracetamol) for postcraniotomy pain:
 systematic review and meta-analysis of randomized controlled trials. World
 Neurosurg. 2020; 134: 569-576.
- Nonaka T, Hara M, Miyamoto C, Sugita M, Yamamoto T. Comparison of the
 analgesic effect of intravenous acetaminophen with that of flurbiprofen axetil
 on post-breast surgery pain: a randomized controlled trial. J Anesth. 2016;30:
 405-409.
- Dastan F, Langari ZM, Salamzadeh J, Khalili A, Aqajani S, Jahangirifard A. A 16. 743 comparative study of the analgesic effects of intravenous ketorolac, 744 morphine 745 paracetamol, and in patients undergoing video-assisted thoracoscopic surgery: a double-blind, active-controlled, randomized clinical 746 trial. Ann Card Anaesth. 2020;23: 177-182. 747
- 17. Sharma CV, Long JH, Shah S, Rahman J, Perrett D, Ayoub SS, et al. First

- evidence of the conversion of paracetamol to AM404 in human cerebrospinal
 fluid. J Pain Res. 2017;10: 2703-2709.
- 751 18. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al.
- 752 SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical
- 753 trials. BMJ. 2013;346: e7586.
- Karcioglu O, Topacoglu H, Dikme O, Dikme O. A systematic review of the
 pain scales in adults: which to use? Am J Emerg Med. 2018;36: 707-714.
- 756 20. Kumar SP. Utilization of brief pain inventory as an assessment tool for pain in
- patients with cancer: a focused review. Indian J Palliat Care. 2011;17:
 108-115.
- Chow SC, Shao J, Wang H. Sample size calculation in clinical research. 2nd
 Ed. New York: Chapman & Hall/CRC Press; 2007.
- 761 22. Ayoub SS. Paracetamol (acetaminophen): A familiar drug with an unexplained
 762 mechanism of action. Temperature (Austin). 2021;8: 351-371.
- 763 23. Ohashi N, Kohno T. Analgesic effect of acetaminophen: a review of known
 764 and novel mechanisms of action. Front Pharmacol. 2020;11: 580289.

FIGURE 1. Flow diagram of patients.



Figure

	Time point				St	udy per	iod				
		Enrollmen	Allocati Post-allocation								
		t	on								ut
		Pre-anesth	Prior to	PAC	30	12 h	24 h	48 h	3	6	12
medRxiv preprint	t doi: https://doi.org/1	esia visit 0.1101/2024.08.27.2431	anesthes 2675; this version po	U osted Augus	min t 28, 2024. 1	after The copyright	after t holder for th	after	mont	mont	months
preprint (which	was not certified by	r peer review) is the aut r is made available under	hor/funder, who has berpetuity. a CC-BY 4.0 Interna	granted med	IRxiv a licen ^{se .} after	se to display surge	the preprint	in surge	hs	hs	after
				у	PAC	ry	ry	ry	after	after	surgery
					U				surge	surge	
					entr				ry	гу	
					у						
-	Enrollment	_	_	_	_	_	_	_		_	
	Eligibility	×	_	_	_	_	_	_	_	_	_
	criteria										
		×	_	_	_	_	_	_	_	_	_
	Written										
	informed										
	consent										

Fig 1. Schedule of patient enrollment, study interventions, and outcomes assessments.

Demograph	×	_	_	_	_	_	_	_	_	_
ic data										
Baseline	×	_	_	_	_	_	_	—	_	_
characteristi										

	cs														
	Randomizat	_	×	_	_	_	_	_	_	_	_				
	ion														
	Allocation	_	×	_	_	_	_	_	_	_	_				
	Interventio	_		_	_	_	_	_	_	_	_				
modPviv	ns doi: https://doi.org/10.1101/2024.08.27.24312675; this version posted August 28, 2024. The copyright holder for this														
preprint (which	Intravenous It is ma	review) is the author, per ade available under a (/funder, who has betuity. CC-BY 4.0 Interna	granted med	Rxiv a licen	se to display	the preprint	in	_	_	_				
	paracetamol														
	and														
	mannitol														
	Normal	_	×		_	_	_	_	—	_	_				
	saline														
	Assessment	_	_	_	_	_	_	_	_	_	_				
	Dosage of	_	_	×	_	_	_	_	_	-	_				
	propofol														
	Dosage of	_	_	×	_	_	_	_	_	_	_				
	remifentanil														
	NRS pain	_	_	×	×	×	×	×	×	×	×				

scores

times PCIA

is pressed

	Nausea and	_	_	_	_	_	_	×	_	_	_
	vomiting										
	Headache	_	_	_	_	_	_	×	_	_	_
	Insomnia	_	_	_	_	_	_	×		_	_
	Itching	_	_	_	_	_	_	×	-	-	_
medRxiv preprin	Respiratory t doi: https://doi.org/10.1101/	2024.08.27.24312675;	this version poste	d August 28	3, 2024. The	copyright ho	Ider for this	×	_	_	_
	depression It is made	e available under a CC	uity. -BY 4.0 Internation	nal license .	iv a license		рерппст				
	Excessive	_	_		_	_	<u></u>	×	_	_	_
	sedation										
	Urinary	_	_	_	_	_		×		_	_
	retention										
	Allergic	_	_	_	_	_		×	_	_	_
	reactions										
	Liver injury	_	_	_	_	_	_	×	_	_	_
	Kidney	_	_	_	_	_	_	×	_	_	_
	injury										
	Surgeon	_	_	_	_	_	_	×	_	_	_
	satisfaction										

Patient	_	_	_	_	_	_	_	_	_	×
satisfaction										
Quality of		_	_	_	_		_	_	_	×
daily life										

According to the SPIRIT 2013 statement defining the standard items for clinical research programs.

NRS, numerical rating scale. PCIA, patient-controlled intravenous analgesia.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.27.24312675; this version posted August 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .